Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

Major depressive disorder is a debilitating condition that impacts around 5% of adults worldwide. While doctors commonly prescribe antidepressants to patients, it has several side effects and might ...

-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control ...

Light may affect the body more than previously assumed. A new study points to a possible link between light exposure and ...

NEW YORK, Oct. 2 (UPI) --Bright-light therapy offers major advantages as an addition to treatment with antidepressants for non-seasonal depressive disorders, a new analysis of 11 randomized clinical ...

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - “DBA/2 is an excellent ...